Trial product was administered using a PDS290 pre-filled pen-injector with a 3 mL cartridge containing semaglutide 1.0 mg/mL or 3.0 mg/mL (depending on dose level) or placebo
Product Name: Glutathione Skin Capsules
Some drugs have been proposed to accelerate -cell loss (e.g., glibenclamide and glyburide) [23], while other drugs such as peroxisome proliferator-activated receptor-gamma (PPAR) agonists, GLP-1 receptor agonists, dipeptidyl peptidase-4 (DPP-4) inhibitors, glycogen synthase kinase 3 (GSK3) inhibitors, or G protein-coupled receptor 40 (GPR40) agonists have been suggested to protect -cell function [16]
This represents the single largest expansion of semaglutide access in US history and is expected to significantly increase prescription volumes in the second half of 2026
Meanwhile, retatrutide will enter the market as a premium branded product
But addiction treatment is complex